Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma

For nearly a decade, sorafenib has served as a first-line chemotherapeutic drug for the treatment of hepatocellular carcinoma (HCC), but it displays only limited efficacy against advanced drug-resistant HCC. Regorafenib, the first second-line drug approved for treatment after sorafenib failure, can...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Aging (Albany NY)
Prif Awduron: Zhu, Qiankun, Ren, Haiyang, Li, Xiaodong, Qian, Bo, Fan, Shengjie, Hu, Fengli, Xu, Lishan, Zhai, Bo
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals 2020
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7746348/
https://ncbi.nlm.nih.gov/pubmed/33203790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/aging.104028
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg